{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Renal+Tumors&page=13", "query": { "condition": "Renal Tumors", "page": 13 }, "page_size": 10 }, "pagination": { "page": 13, "page_size": 10, "total_count": 1797, "total_pages": 180, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Renal+Tumors&page=14&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Renal+Tumors&page=12&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-14T21:14:16.660Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00727532", "title": "Sorafenib in Treating Patients With Locally Advanced or Metastatic Kidney Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Hereditary Clear Cell Renal Cell Carcinoma", "Kidney Cancer" ], "interventions": [ { "name": "Sorafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 9, "start_date": "2008-07", "completion_date": "2013-09", "has_results": true, "last_update_posted_date": "2019-05-03", "last_synced_at": "2026-10-14T21:14:16.660Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00727532" }, { "nct_id": "NCT07517198", "title": "Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor", "Small Cell Lung Cancer (SCLC)", "High Grade Neuroendocrine Cancer", "Small Cell Carcinomas of Non-lung Origin", "Non-small Cell Lung Cancer (NSCLC)", "Prostate Cancer", "Ovarian Cancer", "Renal Carcinoma (Clear and Non-clear Cell)", "Head and Neck Squamous Cell Carcinoma (HNSCC)", "Hepatic Cancer", "Gastric Cancer", "Triple-negative Breast Cancer (TNBC)" ], "interventions": [ { "name": "EXS74539", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2026-04-13", "completion_date": "2029-03", "has_results": false, "last_update_posted_date": "2026-06-10", "last_synced_at": "2026-10-14T21:14:16.660Z", "location_count": 3, "location_summary": "Los Angeles, California • Fort Worth, Texas • West Valley City, Utah", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Fort Worth", "state": "Texas" }, { "city": "West Valley City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT07517198" }, { "nct_id": "NCT01183663", "title": "Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Cancers" ], "interventions": [ { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Sorafenib", "type": "DRUG" }, { "name": "Temsirolimus", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "5-fluorouracil", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 180, "start_date": "2010-08", "completion_date": "2016-05", "has_results": false, "last_update_posted_date": "2016-06-03", "last_synced_at": "2026-10-14T21:14:16.660Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01183663" }, { "nct_id": "NCT04157985", "title": "Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Advanced Solid Tumors", "NSCLC", "Bladder Cancer", "HNSCC", "Renal Cancer", "Melanoma", "Anal Cancer", "Colorectal Cancer", "Cholangiocarcinoma", "Gastric Cancer", "Hepatocellular Carcinoma", "Merkel Cell Carcinoma", "Cervical Cancer" ], "interventions": [ { "name": "Continue PD-1/PD-L1 Inhibitors treatment", "type": "DRUG" }, { "name": "Discontinue PD-1/PD-L1-1 inhibitor", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Dan Zandberg", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 161, "start_date": "2019-11-15", "completion_date": "2025-11-07", "has_results": false, "last_update_posted_date": "2025-12-11", "last_synced_at": "2026-10-14T21:14:16.660Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04157985" }, { "nct_id": "NCT02909452", "title": "Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms", "Neoplasms, Glandular and Epithelial", "Neoplasms by Histologic Type", "Bronchial Neoplasms", "Lung Neoplasms", "Respiratory Tract Neoplasms", "Thoracic Neoplasms", "Digestive System Neoplasms", "Endocrine Gland Neoplasms", "Carcinoma, Non-Small-Cell Lung", "Lung Diseases", "Breast Diseases", "Renal Neoplasm", "Solid Tumors" ], "interventions": [ { "name": "Entinostat", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Syndax Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2016-09-20", "completion_date": "2021-02-09", "has_results": false, "last_update_posted_date": "2022-01-25", "last_synced_at": "2026-10-14T21:14:16.660Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02909452" }, { "nct_id": "NCT00949052", "title": "Genetic Susceptibility and Risk of Second Cancers in Patients Who Have Undergone Stem Cell Transplant for Cancer", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Cancer" ], "interventions": [ { "name": "DNA analysis", "type": "GENETIC" }, { "name": "polymorphism analysis", "type": "GENETIC" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "medical chart review", "type": "OTHER" }, { "name": "questionnaire administration", "type": "OTHER" }, { "name": "assessment of therapy complications", "type": "PROCEDURE" }, { "name": "evaluation of cancer risk factors", "type": "PROCEDURE" } ], "intervention_types": [ "GENETIC", "OTHER", "PROCEDURE" ], "sponsor": "Vanderbilt-Ingram Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 1000, "start_date": "2009-01", "completion_date": "2018-02", "has_results": false, "last_update_posted_date": "2018-08-16", "last_synced_at": "2026-10-14T21:14:16.660Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00949052" }, { "nct_id": "NCT01778933", "title": "Intraoperative Imagery of Renal Nodules With Folate-fluorescein Conjugate(EC17)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Renal Cell Carcinoma" ], "interventions": [ { "name": "EC17", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Pennsylvania", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2013-05", "completion_date": "2014-09", "has_results": false, "last_update_posted_date": "2018-07-03", "last_synced_at": "2026-10-14T21:14:16.660Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01778933" }, { "nct_id": "NCT04320888", "title": "Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hematopoietic and Lymphatic System Neoplasm", "Recurrent Ependymoma", "Recurrent Ewing Sarcoma", "Recurrent Hepatoblastoma", "Recurrent Histiocytic and Dendritic Cell Neoplasm", "Recurrent Langerhans Cell Histiocytosis", "Recurrent Lymphoma", "Recurrent Malignant Germ Cell Tumor", "Recurrent Malignant Glioma", "Recurrent Malignant Solid Neoplasm", "Recurrent Medulloblastoma", "Recurrent Neuroblastoma", "Recurrent Non-Hodgkin Lymphoma", "Recurrent Osteosarcoma", "Recurrent Peripheral Primitive Neuroectodermal Tumor", "Recurrent Rhabdoid Tumor", "Recurrent Rhabdomyosarcoma", "Recurrent Soft Tissue Sarcoma", "Recurrent WHO Grade 2 Glioma", "Refractory Ependymoma", "Refractory Ewing Sarcoma", "Refractory Hepatoblastoma", "Refractory Histiocytic and Dendritic Cell Neoplasm", "Refractory Langerhans Cell Histiocytosis", "Refractory Lymphoma", "Refractory Malignant Germ Cell Tumor", "Refractory Malignant Glioma", "Refractory Malignant Solid Neoplasm", "Refractory Medulloblastoma", "Refractory Neuroblastoma", "Refractory Non-Hodgkin Lymphoma", "Refractory Osteosarcoma", "Refractory Peripheral Primitive Neuroectodermal Tumor", "Refractory Rhabdoid Tumor", "Refractory Rhabdomyosarcoma", "Refractory Soft Tissue Sarcoma", "Refractory WHO Grade 2 Glioma", "Wilms Tumor" ], "interventions": [ { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Radionuclide Imaging", "type": "PROCEDURE" }, { "name": "Selpercatinib", "type": "DRUG" }, { "name": "X-Ray Imaging", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Months", "maximum_age": "21 Years", "sex": "ALL", "summary": "12 Months to 21 Years" }, "enrollment_count": 1, "start_date": "2021-05-03", "completion_date": "2027-06-30", "has_results": true, "last_update_posted_date": "2026-10-09", "last_synced_at": "2026-10-14T21:14:16.660Z", "location_count": 172, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 129 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT04320888" }, { "nct_id": "NCT00903175", "title": "Efficacy and Safety Comparison of RAD001 Versus Sunitinib in the First-line and Second-line Treatment of Patients With Metastatic Renal Cell Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Renal Cell Carcinoma" ], "interventions": [ { "name": "everolimus", "type": "DRUG" }, { "name": "sunitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 471, "start_date": "2009-10", "completion_date": "2015-05", "has_results": true, "last_update_posted_date": "2016-11-08", "last_synced_at": "2026-10-14T21:14:16.660Z", "location_count": 35, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Fayetteville, Arkansas + 31 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00903175" }, { "nct_id": "NCT00513175", "title": "Non-Myeloablative Allogeneic Stem Cell Transplantation With Matched Unrelated Donors for Treatment of Hematologic Malignancies, Renal Cell Carcinoma, and Aplastic Anemia", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Acute Myeloid Leukemia", "Myelodysplasia", "Acute Lymphoblastic Leukemia", "Chronic Lymphocytic Leukemia", "Follicular Lymphoma", "Multiple Myeloma", "NHL", "Myeloproliferative Diseases", "Chronic Myeloid Leukemia", "Renal Cell Carcinoma", "Aplastic Anemia" ], "interventions": [], "intervention_types": [], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "16 Years to 75 Years" }, "enrollment_count": 44, "start_date": "2001-10", "completion_date": "2007-11", "has_results": false, "last_update_posted_date": "2012-11-09", "last_synced_at": "2026-10-14T21:14:16.660Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00513175" } ] }